Gastrounit, Medical Division, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark.
Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark.
Aliment Pharmacol Ther. 2022 Sep;56(6):989-1006. doi: 10.1111/apt.17145. Epub 2022 Jul 28.
Despite the increasing use of biologics in patients with inflammatory bowel disease (IBD), real-world data about outcomes in the era of biologics remain inconclusive.
To investigate trends in surgeries, hospitalisations and medication use in patients with IBD in a multinational, population-based cohort METHODS: We included 42,894 patients with ulcerative colitis (UC) and 24,864 with Crohn's disease (CD) who were diagnosed between 2010 and 2017 in Denmark, Norway and Sweden. We extracted data about surgeries, hospitalisations and medications from national registries and compared across countries and diagnosis years.
Between 2010 and 2017, 2-year surgery rates were 4-7% in UC and 10-15% in CD and were stable over time. Two-year hospitalisation rates increased in Denmark (UC: 20% to 35%; CD: 27% to 32%) but were stable in Norway and Sweden (fluctuating between 33% and 37% in UC, and 46% and 52% in CD). Two-year rates of biologic use increased in both UC (7% to 16% in Denmark, 8% to 18% in Norway) and CD (22% to 26% in Denmark; 21% to 35% in Norway). Two-year rates of immunomodulator use increased in Norway (from 14% to 23% in UC; 37% to 45% in CD) and Sweden (from 41% to 52% in CD), but were stable in Denmark (between 17% and 21% in UC; 39% to 46% in CD).
Between 2010 and 2017, surgery rates among Scandinavian patients with IBD remained stable, with no clear changes in hospitalisation rates despite the increasing use of immunomodulators and biologics.
尽管在炎症性肠病（IBD）患者中越来越多地使用生物制剂，但在生物制剂时代的实际结果仍不确定。
在一个多国家的人群队列中调查 IBD 患者手术、住院和药物使用的趋势。
我们纳入了 2010 年至 2017 年期间在丹麦、挪威和瑞典被诊断为溃疡性结肠炎（UC）的 42894 例患者和克罗恩病（CD）的 24864 例患者。我们从国家登记处提取了手术、住院和药物使用的数据，并在国家和诊断年份之间进行了比较。
2010 年至 2017 年间，UC 的 2 年手术率为 4-7%，CD 的为 10-15%，且呈稳定趋势。丹麦的 2 年住院率增加（UC：20%至 35%；CD：27%至 32%），但挪威和瑞典保持稳定（UC 为 33%至 37%，CD 为 46%至 52%）。UC 的生物制剂使用率在丹麦（7%至 16%）和挪威（8%至 18%）均增加，CD 的在丹麦（22%至 26%）和挪威（21%至 35%）均增加。挪威的免疫调节剂使用率在 UC（从 14%至 23%；CD 从 37%至 45%）和瑞典（从 41%至 52%）中增加，但在丹麦保持稳定（UC 为 17%至 21%；CD 为 39%至 46%）。
2010 年至 2017 年间，斯堪的纳维亚 IBD 患者的手术率保持稳定，尽管免疫调节剂和生物制剂的使用不断增加，但住院率没有明显变化。
